Physician profile
Luisa Delima
NPI 1811536550
$7,874.60
in general payments reported to CMS, 2019-2025
31 companies · $1,712 in 2025
The $1,712 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.51 · 2022: $109 · 2023: $3,044 · 2024: $2,999 · 2025: $1,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,754.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,046.44 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $892.78 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $687.89 | 2022-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $673.82 | 2023-2025 | Xifaxan, Relistor, Trulance |
| Qol Medical, LLC | $390.20 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $372.16 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $329.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $324.59 | 2022-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $277.24 | 2023-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $264.73 | 2024-2025 | Voquezna |
| Pfizer INC. | $190.23 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $165.23 | 2023 | |
| Celgene Corporation | $158.09 | 2023 | Zeposia |
| Aimmune Therapeutics, INC. | $157.30 | 2024-2025 | Zenpep |
| Vivus LLC | $131.52 | 2023-2025 | Pancreaze, Qsymia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $122.36 | 2023-2025 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $97.68 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $90.93 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $88.98 | 2023-2025 | Linzess |
| Janssen Scientific Affairs, LLC | $70.21 | 2023 | Stelara |
| Lilly USA, LLC | $52.40 | 2025 | Omvoh |
| Celltrion USA INC. | $50.27 | 2024 | Vegzelma |
| Redhill Biopharma INC. | $48.67 | 2023-2024 | Talicia, Aemcolo |
| Fresenius Kabi USA, LLC | $46.63 | 2023-2024 | Idacio |
| Evoke Pharma, INC. | $39.63 | 2023-2025 | Gimoti |
| Biocon Biologics INC | $24.75 | 2025 | Yesintek |
| Alnylam Pharmaceuticals INC. | $24.37 | 2024 | Givlaari |
| Amgen INC. | $20.33 | 2023 | Avsola |
| Boston Scientific Corporation | $19.09 | 2023 | Watchman Flx |
| Genentech USA, INC. | $11.51 | 2021 | |
| Organon LLC | $5.05 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luisa Delima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.